Archives
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Elevating Gene Expression Analysis: Next-Gen qPCR for Transl
2026-08-04
This thought-leadership article explores the mechanistic strengths and strategic advantages of the HotStart™ Universal 2X Green qPCR Master Mix for translational researchers. By integrating evidence from antioxidant and anti-aging research, it provides workflow guidance and addresses both the challenges and opportunities in real-time gene expression quantification. The discussion goes beyond typical product summaries, offering actionable insights for designing robust, reproducible studies at the interface of molecular innovation and clinical translation.
-
QSHXO Modulates Autophagy and Ferroptosis in MASLD Models
2026-08-04
Liu et al. demonstrate that Qushi Huoxue ointment (QSHXO) ameliorates metabolic associated steatotic liver disease (MASLD) in mice through coordinated activation of autophagy and inhibition of ferroptosis, providing mechanistic clarity on its hepatoprotective effects. These findings inform the design of targeted interventions and deepen understanding of MASLD pathogenesis.
-
Targeted Delivery of Amikacin into Mycobacterial Granulomas
2026-08-03
This study demonstrates the use of dendritic cells to deliver amikacin directly into granulomas in a mouse model of Mycobacterium avium infection. The innovative approach enables site-specific antibiotic delivery, minimizing systemic toxicity and offering a strategy to overcome challenges in treating persistent nontuberculous mycobacterial infections.
-
FGFR3 Inhibition with NVP-BGJ398 Phosphate Improves SLC26A2
2026-08-03
This study demonstrates that pharmacological inhibition of FGFR3 signaling with NVP-BGJ398 phosphate ameliorates skeletal defects in mouse models of SLC26A2-related chondrodysplasia. The research provides mechanistic and translational evidence that targeting FGFR3 overactivation could offer new therapeutic avenues for rare skeletal diseases.
-
Methylprednisolone: Applied Protocols in Bone Loss & Inflamm
2026-08-02
Methylprednisolone, a potent synthetic glucocorticoid receptor agonist, is foundational for modeling osteonecrosis and inflammation in both in vitro and in vivo systems. This article translates recent mechanistic insights and animal protocols into actionable guidelines, highlighting troubleshooting strategies and workflow enhancements to optimize reproducibility in anti-inflammatory and bone-resorption research.
-
Octenidine Dihydrochloride: Mechanisms and Next-Gen Antisept
2026-08-01
This thought-leadership article explores the mechanistic underpinnings and translational impact of Octenidine dihydrochloride as a chemical antiseptic for laboratory use. By synthesizing evidence from recent research on gemini quaternary ammonium compounds, it offers strategic guidance for researchers navigating the evolving landscape of antimicrobial agents, and contextualizes advances beyond standard product literature.
-
Sulfo-NHS-SS-Biotin Kit: Precise, Reversible Cell Surface La
2026-07-31
The Sulfo-NHS-SS-Biotin Kit (K1006) enables highly specific, water-soluble, amine-reactive biotinylation of proteins and antibodies for purification and interactome mapping. Its unique disulfide-cleavable spacer allows reversible labeling, making it ideal for dynamic studies of cell surface proteins and glycoRNA–RBP nanoclusters. This kit sets a benchmark for selectivity and workflow flexibility in affinity purification and cell surface proteomics.
-
Chloramphenicol in Plasmid Selection: Applied Protocols & In
2026-07-31
Chloramphenicol’s unique mode of action offers stringent, reproducible plasmid selection for molecular biology workflows, especially in the context of tracking resistance gene dynamics. This article translates recent epidemiological findings and technical advances into actionable protocols and troubleshooting guidance for reliable use of APExBIO’s high-purity Chloramphenicol in modern research.
-
Annexin V-FITC/PI Apoptosis Assay Kit: Mechanism & Benchmark
2026-07-30
The Annexin V-FITC/PI Apoptosis Assay Kit provides rapid, fluorescence-based detection of early and late apoptosis in research cells. It distinguishes apoptotic stages by exploiting phosphatidylserine externalization and membrane integrity, offering high specificity for cell death pathway analysis. This product dossier evaluates its biological rationale, mechanism, and evidence benchmarks for precise apoptosis assay deployment.
-
Metabolomics Reveals Resistance in Carbapenemase-Producing E
2026-07-30
This study applies LC-MS/MS metabolomics to distinguish carbapenemase-producing Enterobacterales (CPE) from non-CPE strains, identifying 21 metabolite biomarkers predictive of resistance. These findings offer a rapid, molecularly informed pathway for CPE diagnostics and highlight new metabolic insights into antibiotic resistance.
-
Targeted Delivery of Amikacin into Mycobacterial Granulomas
2026-07-29
This study introduces a dendritic cell-mediated approach for the targeted delivery of amikacin into granulomas during Mycobacterium avium infection in mice. By conjugating amikacin to fluorescein isothiocyanate and loading it into dendritic cells, the research demonstrates effective local antibiotic delivery without increased systemic toxicity, suggesting a promising strategy for enhancing antibiotic efficacy in granulomatous infections.
-
SNORA38B Drives NSCLC Progression and Immunotherapy Response
2026-07-29
This study reveals that SNORA38B, a small nucleolar RNA, acts as an oncogenic driver in non-small cell lung cancer (NSCLC) by promoting tumor growth and immune evasion through the GAB2/AKT/mTOR signaling pathway. Targeting SNORA38B not only suppresses tumorigenesis but also enhances the effectiveness of immune checkpoint blockade, highlighting its potential as both a prognostic biomarker and a therapeutic target.
-
NVP-BGJ398 Phosphate: Mechanistic Advances in FGFR-Targeted
2026-07-28
Explore the scientific depth and translational promise of NVP-BGJ398 phosphate as a selective FGFR inhibitor. This article reveals unique mechanistic insights and practical assay guidance for cancer and skeletal disease research, setting it apart from prior protocol-focused content.
-
ETS1 Regulates Mitophagy via SENP2/HSPA8/FUNDC1 in BPD Model
2026-07-28
This study uncovers ETS1 as a novel transcriptional regulator that mitigates bronchopulmonary dysplasia (BPD) by targeting the SENP2/HSPA8/FUNDC1 axis, thereby inhibiting mitochondrial damage-induced autophagy. The findings reveal a mechanistic link between sumoylation-dependent mitophagy and neonatal lung injury, opening new avenues for targeted molecular interventions.
-
Amikacin Sulfate: Advanced Intracellular Delivery in Researc
2026-07-27
Amikacin Sulfate, a potent aminoglycoside, is redefining antibiotic research with its robust intracellular uptake and targeted delivery—critical for models of non-tuberculous mycobacterial infection. This guide distills best practices, troubleshooting, and innovative workflows to harness Amikacin’s full experimental potential.